Bio-Technology General Corp. announced Tuesday that itsrecombinant human growth hormone has been approved bythe Israeli Ministry of Health to treat Turner's syndrome.

The genetic disorder, in which girls are born with only onehealthy X chromosome instead of two, results in short stature,failure of the ovaries to respond to pituitary stimulation andfailure to develop secondary sexual characteristics.

The New York company estimated the worldwide market to be$700 million annually, and that sales would begin in Israellater this year. Bio-Technology General said it would use theIsrael approval and other data as the basis for applications forapproval in other countries.

(c) 1997 American Health Consultants. All rights reserved.